Syros Pharmaceuticals Inc represents a commitment to pioneering gene control medicines. Their corporate philosophy is built upon the belief that by understanding gene regulation, they can uncover unique and potentially transformative approaches to treat various diseases. Syros focuses on developing therapies that target the regulatory regions of the genome, known as gene control, to harness the power of gene expression and effectively modulate disease-related genes. By employing innovative science and technology, Syros Pharmaceuticals Inc aims to make a positive impact on patients' lives by delivering breakthrough treatments for a range of diseases.

Syros Pharmaceuticals Inc, a leading biopharmaceutical company, primarily operates in the United States of America. With its headquarters in Cambridge, Massachusetts, Syros Pharmaceuticals focuses on pioneering gene control medicines. The company is primarily present in the US and actively engages in research, development, and commercialization of innovative therapies targeting severe genetic diseases and cancer. Syros Pharmaceuticals Inc's unwavering dedication towards transforming patients' lives through cutting-edge treatments has solidified its position as a prominent player in the US biopharmaceutical industry.

Syros Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2016, raising funds to support its research and development efforts. Syros Pharmaceuticals Inc also entered into partnerships with leading pharmaceutical companies, such as Global Blood Therapeutics and Incyte Corporation, to advance its pipeline of novel gene control medicines. Furthermore, the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead product candidate, SY-1425, in the treatment of acute myeloid leukemia (AML). These accomplishments highlight Syros Pharmaceuticals Inc's commitment to advancing innovative therapies and solidifying its position in the biopharmaceutical industry.

Syros Pharmaceuticals Inc is a renowned biopharmaceutical company headquartered in Cambridge, Massachusetts. Established in 2011, Syros specializes in developing innovative gene control therapies. The company leverages its deep expertise in gene regulation and groundbreaking technologies to discover and develop novel medicines. By focusing on gene activation and repression, Syros aims to address various diseases with unmet medical needs, including cancer and genetic disorders. Syros has a robust pipeline of potential therapies backed by years of research and collaboration with esteemed scientific institutions. With its dedication to advancing precision medicine, Syros Pharmaceuticals Inc continues to make significant strides in improving patient outcomes and revolutionizing the healthcare industry.

Some of the main competitors of Syros Pharmaceuticals Inc in the market include Celgene Corporation, Gilead Sciences Inc, and Novartis AG.

Syros Pharmaceuticals Inc is primarily active in the biotechnology industry.

The business model of Syros Pharmaceuticals Inc is focused on discovering and developing small molecules that control the expression of genes. They aim to target gene regulatory proteins to treat various diseases, including cancer and genetic diseases. By leveraging their expertise in gene control, Syros Pharmaceuticals Inc intends to develop innovative therapeutics that can address unmet medical needs and improve patient outcomes.

KGV kan for øyeblikket ikke beregnes for Syros Pharmaceuticals.

KUV kan for øyeblikket ikke beregnes for Syros Pharmaceuticals.

AlleAktien Kvalitetsscore kan for tiden ikke beregnes for Syros Pharmaceuticals.

Omsetningen kan for øyeblikket ikke beregnes for Syros Pharmaceuticals.

Resultatet kan for øyeblikket ikke beregnes for Syros Pharmaceuticals.

Syros Pharmaceuticals specializes in the discovery and development of new therapeutic options for genetically-based diseases. The company uses advanced genetic research technologies to examine cellular processes and identify genetic patterns in different disease processes. The goal is to develop both drugs and diagnostic tests based on this knowledge. Syros Pharmaceuticals' business model is based on identifying genetic patterns in diseases, with the aim of gaining information about the genes and pathways that cause diseases such as cancer and autoimmune diseases. This information is then used to identify new therapeutic approaches and develop medications that target the underlying genetic cause. The company has developed a platform called the Gene Control Drug Discovery Platform to identify specific genes and pathways responsible for the development of diseases. This platform also helps identify new targets that can be used in the development of future medications. Syros has a pipeline of therapeutic candidates in various stages of clinical development. For example, the company has initiated a Phase 2 study for an SNS-062 inhibitor of Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's patients. The LRRK2 inhibitor is a potential medication for the treatment of Parkinson's and other neurodegenerative diseases. The company also has a partnership with Incyte to develop "Oral BET" alias "INCB50465" - a potential cancer medication that aims to block epigenetic circuits. In addition, there is a collaboration with Alzheimer's Research UK to better understand the mechanisms of Alzheimer's disease and develop new therapies. Syros also offers services such as its "Cell Engineering Services," which help researchers create and test genetically modified cells for use in drug development. The company also provides diagnostic tests that can diagnose the underlying genetic causes of various diseases. In conclusion, Syros Pharmaceuticals' business model revolves around discovering and developing drugs and diagnostic tests that focus on the underlying genetic cause of diseases. The company utilizes its Gene Control Drug Discovery Platform and pipeline of therapeutic candidates to advance the discovery and development of new medications. In addition to its services, Syros collaborates with other organizations to expand knowledge about various disease processes and better understand how genetic factors play a role.

Syros Pharmaceuticals utbetaler et dividende på 0 USD fordelt over utdelinger i året.

Utbyttet kan for øyeblikket ikke beregnes for Syros Pharmaceuticals eller så utdeler ikke selskapet utbytte.

ISIN-en til Syros Pharmaceuticals er US87184Q1076.

WKN for Syros Pharmaceuticals er A2AP4X.

Tikkeren til Syros Pharmaceuticals er SYRS.

I løpet av de siste 12 månedene utbetalte Syros Pharmaceuticals et utbytte på . Dette tilsvarer en utbytteavkastning på ca. . For de neste 12 månedene vil Syros Pharmaceuticals sannsynligvis betale et utbytte på 0 USD.

Utdelingsrendementet til Syros Pharmaceuticals er for øyeblikket .

Syros Pharmaceuticals betaler utbytte kvartalsvis. Dette blir utdelt i månedene .

Syros Pharmaceuticals betalte utbytte hvert år de siste 0 årene.

For de kommende 12 månedene forventes det utbytter på 0 USD. Dette tilsvarer en utbytteavkastning på 0 %.

Syros Pharmaceuticals tilordnes sektoren 'Helse'.

For å motta den siste utbyttet fra Syros Pharmaceuticals den på 0 USD, måtte du ha aksjen i porteføljen din før ex-datoen den .

Utbetalingen av det siste utbyttet fant sted den .

I løpet av 2023 ble det utbetalt 0 USD i utbytte fra Syros Pharmaceuticals.

Utdelingene fra Syros Pharmaceuticals blir betalt ut i USD.